Duke Cancer Institute ( Site 0042)

Durham, North Carolina 27710

0 studies enrolling now · 1 studies all time

What they study most

Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma

Studies at this site

• Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) — Completed